MedTrace Logo

Clinical Study of mRNA Vaccine in Patients With Liver Cancer After Operation

NCT05761717 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2023-03-09

No results posted yet for this study

Summary

This is an open, one-arm study to evaluate the safety and efficacy of mRNA personalized tumor vaccine (tumor vaccine) encoding neonatal antigen in combination with Sintilimab injection for adjuvant prevention of postoperative recurrence of hepatocellular carcinoma.

Conditions

  • Posto Perative Hepatocellular Carcinoma

Interventions

DRUG

Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection

Subcutaneous Injection

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-20
Primary Completion
2025-03-12
Completion
2025-06-12

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05761717 on ClinicalTrials.gov